SCHEMBL2123358

SCHEMBL2123358

Cc1cccc(-c2nc3c(C#N)c[nH]n3c2Nc2cccc(C(F)(F)F)c2)n1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 5/20 0.50
▸ MAPT P10636 3/20 0.41
▸ TP53 P04637 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ EGFR P00533 1/20 0.40
▸ ERBB2 P04626 1/20 0.40
▸ HTT P42858 1/20 0.39
▸ LRRK2 Q5S007 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ IDH2 P48735 1/20 0.38
▸ TEAD1 P28347 1/20 0.38
▸ TEAD4 Q15561 1/20 0.38
▸ TEAD2 Q15562 1/20 0.38
▸ TEAD3 Q99594 1/20 0.38
▸ LMNA P02545 2/20 0.38
▸ THRB P10828 1/20 0.38
▸ MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2125958 0.87 KDM5A (0.48) KDM5AMAPTTP53GAAEGFR
SCHEMBL2124708 0.85 MAPT (0.42) KDM5AMAPTTP53EGFRERBB2
SCHEMBL2122308 0.85 KDM5A (0.55) KDM5AMAPTTP53IDH2
SCHEMBL2873308 0.84 KDM5A (0.51) KDM5AMAPTTP53GAAEGFR
SCHEMBL2866440 0.83 KDM5A (0.54) KDM5AMAPTTP53IDH2
SCHEMBL2122450 0.82 KDM5A (0.51) KDM5AMAPTTP53GAA
SCHEMBL2126696 0.82 MAPT (0.54) KDM5AMAPTTP53GAAEGFR
SCHEMBL2125620 0.81 KDM5A (0.48) KDM5AMAPTTP53GAAEGFR
SCHEMBL2123865 0.81 KDM5A (0.50) KDM5AMAPTTP53GAAEGFR
SCHEMBL2873341 0.80 TGFBR1 (0.45) MAPTTP53GAAKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
EP-2443123-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) Rigel Pharmaceuticals, Inc. (US) 2012-04-25 — — EP disclosed
WO-2010147898-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS, INC. (US) 2010-12-23 — — WO disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK KDM5A 1592/4885MAPT 4045/4885TP53 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback